Royalty Pharma annual return on equity
2019
2020
2021
2022
2023
2024
2025
Royalty Pharma Return on Equity (ROE) Growth & History (RPRX)
Royalty Pharma's return on equity was 7.69% for fiscal 2025.
View full Royalty Pharma company overviewRoyalty Pharma annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 7.69% | −0.72 pp |
| 2024 | 2024-12-31 | 8.41% | −3.16 pp |
| 2023 | 2023-12-31 | 11.57% | +11.14 pp |
| 2022 | 2022-12-31 | 0.43% | −5.72 pp |
| 2021 | 2021-12-31 | 6.15% | −6.01 pp |
| 2020 | 2020-12-31 | 12.16% | −31.76 pp |
| 2019 | 2019-12-31 | 43.92% | — |
Royalty Pharma quarterly return on equity
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.18% | −0.15 pp |
| Q1 2026 | 2026-03-31 | 3.00% | +0.62 pp |
| Q4 2025 | 2025-12-31 | 2.18% | +0.16 pp |
| Q3 2025 | 2025-09-30 | 3.02% | −2.42 pp |
| Q2 2025 | 2025-06-30 | 0.33% | −0.71 pp |
| Q1 2025 | 2025-03-31 | 2.38% | +2.33 pp |
| Q4 2024 | 2024-12-31 | 2.02% | −3.01 pp |
| Q3 2024 | 2024-09-30 | 5.44% | +4.69 pp |
| Q2 2024 | 2024-06-30 | 1.04% | −1.28 pp |
| Q1 2024 | 2024-03-31 | 0.05% | −3.47 pp |
| Q4 2023 | 2023-12-31 | 5.03% | +9.60 pp |
| Q3 2023 | 2023-09-30 | 0.74% | −0.63 pp |
| Q2 2023 | 2023-06-30 | 2.32% | −0.65 pp |
| Q1 2023 | 2023-03-31 | 3.52% | +3.01 pp |
| Q4 2022 | 2022-12-31 | −4.57% | −4.65 pp |
| Q3 2022 | 2022-09-30 | 1.37% | +0.39 pp |
| Q2 2022 | 2022-06-30 | 2.96% | −1.39 pp |
| Q1 2022 | 2022-03-31 | 0.51% | −0.19 pp |
| Q4 2021 | 2021-12-31 | 0.08% | — |
| Q3 2021 | 2021-09-30 | 0.98% | −2.05 pp |
| Q2 2021 | 2021-06-30 | 4.35% | −1.34 pp |
| Q1 2021 | 2021-03-31 | 0.70% | — |
| Q3 2020 | 2020-09-30 | 3.03% | — |
| Q2 2020 · Jun 30 | 2020-06-30 | 5.69% | — |
Royalty Pharma return on equity trends
Over the last five fiscal years, Royalty Pharma's return on equity decreased from 12.16% to 7.69%, a change of −4.47 percentage points. The latest reported quarter, Q2 2026, shows 0.18%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Royalty Pharma source filings ↗